CN115335411A - 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 - Google Patents
一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 Download PDFInfo
- Publication number
- CN115335411A CN115335411A CN202180023395.5A CN202180023395A CN115335411A CN 115335411 A CN115335411 A CN 115335411A CN 202180023395 A CN202180023395 A CN 202180023395A CN 115335411 A CN115335411 A CN 115335411A
- Authority
- CN
- China
- Prior art keywords
- tgf
- antibody
- fusion protein
- beta
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
提供了多种含有截短形式TGFβR2及其与EGFR抗体HPA8构建的融合蛋白,还提供了编码该抗体的核酸(包括重/轻链可变区)、含有该核酸的载体、药物组合物和试剂盒;还提供了制备的截短形式TGFβR2受体蛋白与靶向EGFR和其它多种肿瘤靶点抗体的融合蛋白。
Description
PCT国内申请,说明书已公开。
Claims (26)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010351280 | 2020-04-28 | ||
CN2020103512806 | 2020-04-28 | ||
PCT/CN2021/089782 WO2021218883A1 (zh) | 2020-04-28 | 2021-04-26 | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115335411A true CN115335411A (zh) | 2022-11-11 |
Family
ID=78331770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180023395.5A Pending CN115335411A (zh) | 2020-04-28 | 2021-04-26 | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230257469A1 (zh) |
EP (1) | EP4144764A1 (zh) |
JP (1) | JP2023523981A (zh) |
KR (1) | KR20230003114A (zh) |
CN (1) | CN115335411A (zh) |
AU (1) | AU2021264846A1 (zh) |
BR (1) | BR112022021785A2 (zh) |
CA (1) | CA3176671A1 (zh) |
MX (1) | MX2022013455A (zh) |
WO (1) | WO2021218883A1 (zh) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2542590T4 (da) * | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
PL2970512T3 (pl) * | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
CN105658672A (zh) * | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
BR112016021717A2 (pt) * | 2014-03-21 | 2018-07-10 | Abbvie Inc | anticorpos anti-egfr e conjugados anticorpo-fármaco |
KR102635723B1 (ko) * | 2017-05-04 | 2024-02-08 | 악셀레론 파마 인코포레이티드 | Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도 |
CA3061791A1 (en) * | 2017-05-12 | 2019-10-29 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing tgf-.beta. receptor and medicinal uses thereof |
WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
CN108250297B (zh) * | 2018-01-23 | 2021-07-23 | 上海生物制品研究所有限责任公司 | 抗egfr抗体、其制法及其应用 |
CN110467676B (zh) * | 2019-09-24 | 2020-06-05 | 武汉奥科博泰生物科技有限公司 | 特异性结合egfr的单克隆抗体及其抗癌用途 |
-
2021
- 2021-04-26 MX MX2022013455A patent/MX2022013455A/es unknown
- 2021-04-26 WO PCT/CN2021/089782 patent/WO2021218883A1/zh unknown
- 2021-04-26 US US17/922,327 patent/US20230257469A1/en active Pending
- 2021-04-26 AU AU2021264846A patent/AU2021264846A1/en active Pending
- 2021-04-26 JP JP2022565668A patent/JP2023523981A/ja active Pending
- 2021-04-26 CA CA3176671A patent/CA3176671A1/en active Pending
- 2021-04-26 CN CN202180023395.5A patent/CN115335411A/zh active Pending
- 2021-04-26 EP EP21796635.7A patent/EP4144764A1/en active Pending
- 2021-04-26 KR KR1020227041598A patent/KR20230003114A/ko active Search and Examination
- 2021-04-26 BR BR112022021785A patent/BR112022021785A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021218883A1 (zh) | 2021-11-04 |
JP2023523981A (ja) | 2023-06-08 |
BR112022021785A2 (pt) | 2022-12-06 |
KR20230003114A (ko) | 2023-01-05 |
US20230257469A1 (en) | 2023-08-17 |
EP4144764A1 (en) | 2023-03-08 |
CA3176671A1 (en) | 2021-11-04 |
AU2021264846A1 (en) | 2022-12-08 |
MX2022013455A (es) | 2022-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
WO2020043184A1 (zh) | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 | |
WO2017049452A1 (zh) | 抗人cd137的完全人抗体及其应用 | |
JP2022515318A (ja) | 抗体及びその用途 | |
CN110577597A (zh) | 一种阻断CD47和SIRPα相互作用的抗体 | |
JP7209464B2 (ja) | ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体 | |
WO2017197199A1 (en) | Novel angiopoietin 2, vegf dual antagonists | |
JP2013502445A (ja) | 抗vegfモノクローナル抗体およびその抗体を含む薬学的組成物 | |
JP2023153984A (ja) | 腫瘍治療薬及びその応用 | |
CN114127106B (zh) | 人源化抗VEGF Fab抗体片段及其用途 | |
WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
KR20230132544A (ko) | 신규한 항-그렘린1 항체 | |
CN112513097B (zh) | 四价对称双特异性抗体 | |
CN114008075A (zh) | 人源化抗vegf单克隆抗体 | |
CN110343178B (zh) | 抗人lag-3单克隆抗体及其应用 | |
CN114667296B (zh) | 一种双特异性抗体及其用途 | |
KR102291725B1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2018035119A9 (en) | Methods of treating cancer using bifunctional molecules that target growth factors | |
CN115335411A (zh) | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 | |
CN113754773A (zh) | 一种抗pd1×pdl1的双特异性抗体 | |
JP2022517216A (ja) | 組換え抗ヒトpd-1抗体およびその用途 | |
CN114206941B (zh) | 抗her2/抗4-1bb双特异性抗体及其用途 | |
TWI789679B (zh) | 抗人程序性死亡配體-1(pd-l1)的抗體及其用途 | |
WO2023109888A1 (zh) | 抗ang2-vegf双特异性抗体及其用途 | |
CN114539419B (zh) | 四价对称双特异性抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075930 Country of ref document: HK |